GCM
ORIC icon

Graham Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Graham Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$373K Sell
29,434
-52,142
-64% -$592K 0.01% 723
2025
Q4 		$667K Buy
+81,576
New +$939K 0.02% 520
2022
Q2 		– Sell
-73,919
Closed -$394K – 1181
2022
Q1 		$394K Buy
+73,919
New +$666K 0.01% 641

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Graham Capital Management's ORIC Position: Q1 2026 in Review

Graham Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 64% in Q1 2026, selling an estimated $592K and leaving 29,434 shares worth $373K. The position accounts for 0.01% of the portfolio, ranked #723.

Graham Capital Management first reported a position in ORIC in Q1 2022 and has held it in 3 quarters since. The position peaked at $667K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Graham Capital Management held 29,434 shares of Oric Pharmaceuticals worth $373K as of Q1 2026.
  • Graham Capital Management sold 52,142 Oric Pharmaceuticals shares in Q1 2026, an estimated $592K.
  • Oric Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #723 holding.
  • Graham Capital Management first reported a position in Oric Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • Graham Capital Management's Oric Pharmaceuticals position peaked at $667K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.